Abstract
Cardiovascular and cerebrovascular diseases continue to be leading causes of death throughout the world. Blood platelets play a pivotal role not only in haemostasis but also in the pathogenesis of thrombosis and atherosclerosis, platelet aggregation being an essential step in the formation of either an effective haemostatic plug or an intravascular thrombus. The benefits of various antiplatelet therapies ranging from aspirin, ticlopidine, Clopidogrel, and intravenous platelet GPIIb / IIIa antagonists in various thromboembolic disorders are well documented. Despite of the success of intravenous acute GPIIb / IIIa blockade when given in conjunction with heparin, chronic oral GPIIb / IIIa antagonists with or without aspirin failed in various cardiovascular settings. This review highlights the role of the various antiplatelet therapies in thrombotic disorders as well as future directions.
Keywords: antiplatelet therapies, cerebrovascular diseases, atherosclerosis, intravascular thrombus, clopidogrel, platelet gpIIb/IIIa antagonists, thromboembolic disorders, thrombotic disorders
Current Pharmaceutical Design
Title: Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Volume: 9 Issue: 28
Author(s): Shaker A. Mousa
Affiliation:
Keywords: antiplatelet therapies, cerebrovascular diseases, atherosclerosis, intravascular thrombus, clopidogrel, platelet gpIIb/IIIa antagonists, thromboembolic disorders, thrombotic disorders
Abstract: Cardiovascular and cerebrovascular diseases continue to be leading causes of death throughout the world. Blood platelets play a pivotal role not only in haemostasis but also in the pathogenesis of thrombosis and atherosclerosis, platelet aggregation being an essential step in the formation of either an effective haemostatic plug or an intravascular thrombus. The benefits of various antiplatelet therapies ranging from aspirin, ticlopidine, Clopidogrel, and intravenous platelet GPIIb / IIIa antagonists in various thromboembolic disorders are well documented. Despite of the success of intravenous acute GPIIb / IIIa blockade when given in conjunction with heparin, chronic oral GPIIb / IIIa antagonists with or without aspirin failed in various cardiovascular settings. This review highlights the role of the various antiplatelet therapies in thrombotic disorders as well as future directions.
Export Options
About this article
Cite this article as:
Mousa A. Shaker, Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond, Current Pharmaceutical Design 2003; 9 (28) . https://dx.doi.org/10.2174/1381612033453893
DOI https://dx.doi.org/10.2174/1381612033453893 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nano- and Biotechnological Approaches in Current and Future Generation of Cardiovascular Stents
Current Nanoscience The Role of Heat Shock Protein 90 and Endothelial Nitric Oxide Synthase Signaling in Cardiovascular Therapy
Current Signal Transduction Therapy Editorial (Thematic Issue: Multidisciplinary Imaging of the Coronary Circulation: A Fast Moving Field)
Recent Patents on Medical Imaging Extra-Hematopoietic Effects of Erythropoietin
Cardiovascular & Hematological Disorders-Drug Targets Radiocontrast Nephropathy: Progress not Prevention
Current Cardiology Reviews Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double –Edged Sword!
Recent Advances in Cardiovascular Drug Discovery (Discontinued) CD36 as a Multiple-Ligand Signaling Receptor in Atherothrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets Use of Radiopharmaceuticals for Diagnosis, Treatment, and Follow-Up of Differentiated Thyroid Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Role of Adiponectin in the Metabolic Syndrome: Current Perspectives on its Modulation as a Treatment Strategy
Current Pharmaceutical Design Hypertension and Ischemic Heart Disease in Women
Current Pharmaceutical Design Recent Progress on Chemical Biology of Pluripotent Stem Cell Selfrenewal, Reprogramming and Cardiomyogenesis
Recent Patents on Regenerative Medicine Sleep-Disordered Breathing and Cardiovascular Disease: Exploring Pathophysiology and Existing Data
Current Respiratory Medicine Reviews Ivabradine: The Hope for a Good Treatment of Ischemic Heart Disease
Current Medicinal Chemistry Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets Pathophysiology of Coronary Thrombus Formation and Adverse Consequences of Thrombus During PCI
Current Cardiology Reviews Autologous Adipose-Derived Regenerative Cells for Therapeutic Angiogenesis
Current Pharmaceutical Design Role of Diagnostic Ultrasound in Patient Selection for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Peripheral Blood Derived Cell Trafficking for Cardiac Regeneration
Current Stem Cell Research & Therapy